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Copyright © 200? JCBN Summary We treated patients with C-viral chronic hepatitis (CH) and liver cirrhosis (LC)
with polaprezinc and determined prospectively the effect on long-term outcome. 62 patients
were enrolled. Of these, 32 were administered 1.0 g polaprezinc and the remainder were not
administered polaprezinc. We measured the serum zinc concentrations using conventional
atomic absorption spectrometry and conducted a prospective study to determine the long-term
outcome of the polaprezinc therapy. Changes of aspartate aminotransferase (AST) and alanine
aminotransferase (ALT) levels in the polaprezinc administration group were significantly
lower than those of the untreated group. The decrease in platelet count was clearly less than
that of the untreated group. The factors that inhibited increases in serum zinc concentrations
following administration of polaprezinc included low serum zinc concentration states.
Furthermore, the reductions of AST and ALT levels in the low zinc group were significantly
greater than those of the high zinc group. When the patients who were administered polaprezinc
were divided into two groups whose zinc concentrations increased (zinc responders) or
remained stable or decreased (zinc non-responders), the zinc responders had a clearly lower
cumulative incidence of HCC than the zinc non-responders. We conclude zinc supplementa-
tion improved the long-term outcome in C-viral CH and LC patients.
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Introduction
Zinc is an essential trace element in the human body, with
approximately two grams in healthy adults. The daily
amount of zinc required by an adult is 10–15 mg and this is
absorbed primarily from the upper gastrointestinal tract,
especially the small intestine [1, 2]. Zinc is involved in the
activation of approximately 300 different metallo-enzymes
and metal-activated enzymes in vivo and is regarded as
essential for the metabolism of nucleic acids and proteins
[3, 4]. Therefore, it has been determined that zinc deficiency
causes various pathological conditions in humans. Among
these, it is known that, in patients with C-viral chronic liver
disease, the blood zinc concentration decreases with
progression of the disease from chronic hepatitis (CH) to
compensated liver cirrhosis (LC), to decompensated LC, to
hepatocellular carcinoma (HCC) [5–9]. It is also known that
patients with liver failure or HCC are in an especially severe
state of zinc deficiency and the liver damage is found to
improve with zinc supplementation [10, 11]. Recently, it was
reported that the hepatitis C virus (HCV) NS5A protein is a
zinc metalloprotein and that zinc is closely involved in the
activation of the NS5A protein [12]. Also, it has beenZinc Supplementation in Hepatitis C
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reported that the rate of HCV eradication is higher when
interferon (IFN) therapy for C-viral CH is combined with
zinc supplementation, compared to IFN therapy alone [5, 13].
Thus, it would appear that zinc supplementation has a clear
influence on the clinical profiles of C-viral CH or LC.
However, there has been no report to date as to what
influence zinc supplementation has on the long-term out-
come of C-viral CH or LC. We gave polaprezinc (orally
administered, 150 mg/day) to patients with C-viral CH or
LC and studied prospectively the influence of zinc supple-
mentation on the long-term outcome.
Patients and Methods
Patients
A total of 70 Japanese patients with CH or LC, who were
examined by the first author at Nihon University Itabashi
Hospital from September 1999 through January 2001, gave
informed consent to their participation in this study. All of
the patients were positive for serum HCV RNA (Amplicor
HCV Monitor, Roche Diagnostic K.K., Tokyo, Japan) and
were observed for more than three years. All were negative
for serum hepatitis B surface antigen (HBsAg, enzyme-linked
immunosorbent assay, EIA, Dinabot, Tokyo, Japan), LE
cells, anti-smooth muscle antibody (fluorescence antibody
method, FA), and anti-mitochondria antibody (FA). No
heavy drinkers (more than 30 g ethanol intake per day)
were included in the study. Patients whose blood alanine
aminotransferase (ALT) levels remained persistently in the
abnormal range (>40 international units; IU/L) for more than
6 months were enrolled in the study. The criteria for
diagnosing patients as having LC were as follows: continua-
tion of abnormal blood ALT levels for more than 6 months,
ICGRs of more than 10% at 15 min, platelet counts below
100,000/mm3, the presence of esophageal varices, and the
presence of LC pattern and splenomegaly on abdominal
diagnostic imaging. Blood samples were obtained only from
patients who gave informed consent. The follow-up
schedule was as follows: the patients underwent abdominal
ultrasonography every 3 or 6 months, and abdominal CT
examination every 6 to 12 months, for the detection of
HCC. When space occupying lesions (SOL) were detected
in the livers of patients with CH or LC by dynamic CT
during the time periods stated above, enhancement of SOL
was observed at the early phase of dynamic CT and the
disappearance of SOL staining was observed at the late
phase. A precise diagnosis was made by abdominal angio-
graphy. When SOL in the liver were not enhanced in the
early phase of dynamic CT, or if a precise diagnosis by
abdominal angiography could not be made, tumor biopsy
was carried out and a precise diagnosis was made on the
basis of the pathological findings. Blood samples were
collected on this occasion and stored frozen at −80°C.
Study design
According to the χ2 test, when the event occurrence rate of
the control group is set to 30% and that of the treated group
is set to 10%, the number of cases required to obtain a
significant difference between the event occurrence rates is
62. Therefore, we planned to study 35 cases in the treated
group and 35 cases in the untreated group. The HCV RNA
positive patients who visited first author’s outpatient clinic
between September 1999 and January 2001 numbered 175.
Among 85 of these patients, it was estimated that 5 were
asymptomatic HCV carriers, 50 had achieved ALT levels
continuously within the normal range following medication,
20 had been treated with IFN alpha, and 10 diagnosed as
HCC. The remaining 90 patients (51.4%) were the target
population for this study; they had declined to give their
consent for IFN therapy or had been treated but achieved
only low sustained virologic response (SVR) rates because
of refractory chronic hepatitis C, or IFN therapy was con-
traindicated because of complications such as depression,
interstitial pneumonia, renal dysfunction, cardiovascular
disease, etc., or they did not wish to receive IFN admin-
istration because of the relatively high frequency of
complications and side effects of IFN or ribavirin therapy.
Furthermore, IFN therapy is not indicated by national
insurance criteria for patients diagnosed with LC in Japan.
The reason we selected a study population who had not
undergone IFN therapy was as follows: because IFN therapy
may lead to a reduction in serum zinc concentrations or may
affect the absorption of zinc from the small intestine, it was
thought possible that IFN therapy could influence the serum
zinc concentration in treated patients.
The patients who were treated with polaprezinc gave their
consent to administration of the drug after the benefits and
potential risks had been explained to them. Furthermore, the
benefits and potential risks of administration of Rebamipide
(Mucosta; Otsuka pharmaceutical, Osaka, Japan) and
Teprenone (Selbex; Eizai, Tokyo, Japan) also were explained
to them. These patients were randomized following a
complete explanation of the purpose of the study, namely to
determine whether administration of polaprezinc or other
drugs modified the clinical profiles in the subjects and other
effects of zinc supplementation. The patients who agreed to
take polaprezinc or the other drugs were permitted to choose
which drug they preferred. Therefore, we administered
polaprezinc to patients with CH or LC who opted for zinc
supplementation after detailed explanation and we admin-
istered the other drugs to patients with CH or LC who chose
not to take zinc supplementation. No consent to administra-
tion of these drugs was obtained from 10 patients. In the
final analysis, there were 36 treated and 34 untreated cases.
All 70 patients gave their consent to participate in the study.
The study period was planned initially to continue for three
years from when observations commenced. Among the 70S. Matsuoka et al.
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patients, three with CH and one with LC stopped visiting the
clinic during the three year period. Furthermore, during the
study period, IFN therapy was initiated in four patients at
their request. Therefore, in the final analysis, there were
32 patients in the polaprezinc treated group and 30 in the
untreated group. The clinical background factors of the
patients are shown in Table 1a, which compares the clinical
background factors between patients with CH and LC, and
Table 1b, which compares the clinical background factors
between patients with and without zinc supplementation.
The primary end points were set as aspartate amino-
transferase (AST), ALT and HCV RNA levels, platelet
counts, and the occurrence of HCC. For the C-viral CH and
LC patients, the initial collection of blood was made on the
day of registration. The second collection of blood was made
one year later and the third, within the following two years.
We measured the zinc concentrations of these samples and
investigated the changes in zinc concentrations from the day
of registration. This study was in a accordance with the
ethical standards as formulation in the Helsinki Declaration
of 1975.
Administration of polaprezinc
1.0 g Promac® (ZERIA Pharmaceutical Co., Ltd., Tokyo,
Table 1.
a Comparison of clinical characteristics between patients with chronic hepatitis
and liver cirrhosis (n = 62)
* Median (range). a AST, Aspartate aminotransferase; the upper limit of the normal
range is 38 IU per liter. b ALT, Alanine aminotaransferase; the upper limit of the
normal range is 44 IU per liter. c Kilointernational unit.
Parameter Chronic hepatitis Liver Cirrhosis
Number 48 (77.4%) 14 (22.6%)
Gender (male) 33 (68.8%) 5 (35.7%)
Age 59.0 (26–72) 62.5 (45–74)
ASTa (U/L) 54.0 (25–131) 78.0 (46–138)
ALTb (U/L) 73.0 (27–231) 83.5 (36–201)
Platelet count (×10−4) 17.3 (13–26.4) 9.75 (6.3–12.6)
HCV genotype
1b 38 (79.2%) 14 (100%)
2a 7 (14.6%) 0
2b 3 (6.3%) 0
HCV RNA level (kiuc/ml) 480.5 (8.4–850) 725.0 (7.4–850)
Observation period (years) 5.04 (3.17–6.4) 4.6 (3.32–5.43)
b  Comparison of clinical characteristics between patients with and without zinc
supplementation. (n = 62)
Parameter Promac administrations Controls
Number 30 32
Chronic hepatitis
Liver cirrhosis
Gender (male) 33 (68.8%) 5 (35.7%)
Age 55.9 (26–72) 61.4 (46–74)
AST (U/L) 61.0 (40–118) 82.1 (46–138)
ALT (U/L) 86.3 (41–231) 93.39 (45–201)
Platelet count (×10−4) 18.2 (13–26.4) 8.9 (6.3–10.0)
HCV
1b 38 (79.1%) 14 (100%)
2a 7 (14.6%) 0
2b 3 (6.3%) 0
HCV RNA level (kiu/ml) 499.6 (8.4–850) 576.0 (7.4–850)
Observation period (years) 5.04 (3.12–5.46) 4.59 (3.05–5.43)Zinc Supplementation in Hepatitis C
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Japan) containing 150 mg polaprezinc was administered
orally twice daily: after breakfast and after dinner. Medica-
tions administered prior to the study were continued during
the study. Patients whose serum zinc concentrations had
increased by more than 5.0 μg/ml three years after the study
began, compared to the start of the study, were classified as
zinc responders, while those whose zinc concentrations
remained within 5.0 µg/ml were zinc non-responders (stable),
and those whose zinc concentrations decreased more than
5.0 μg/ml were zinc non-responders (decreased).
Measurement of serum zinc concentrations
Serum zinc concentrations were evaluated using conven-
tional atomic absorption spectrometry using a Z-6100
polarized Zeeman Atomic Absorption Spectrophotometer
(HITACHI, Tokyo, Japan) within 48 h of collection of blood
[14, 15]. Silicone-coated syringes and needles were used for
collecting the blood, which was transferred into zinc-free
test tubes. Serum separation was done carefully to avoid
haemolysis.
Haematological and biochemical examinations
Serum levels of AST, levels of ALT, platelet counts and
HCV RNA concentrations were determined once every two
months. Determination of HCV RNA concentrations was
performed using the Amplicor monitor method (Amplicor
HCV Monitor, Roche Diagnostic K.K.). The results of HCV
RNA testing were classified into low and high groups
according to whether the value was greater or less than
100 kilo international units (kiu)/ml. Determination of HCV
genotype was performed by the method of Okamoto et al.
[16] and the results were interpreted according to the classi-
fication of Simmonds et al. [17].
Long-term outcome of patients
We compared the long-term outcome of patients with CH
or LC in terms of the cumulative probability of occurrence
of HCC, according to whether they were treated with pola-
prezinc or untreated and according to changes in serum
concentrations of zinc.
Statistical analysis
The serum concentrations of zinc were compared using
the chi-square test for independence. Cumulative incidence
curves were determined with the Kaplan-Meier method
and the differences between groups were assessed using the
log-rank test. The remaining parameters were compared
using analysis of variance and Fisher’s Protected Least
Significant difference post hoc test with Statview 4.5 soft-
ware (Abacus Concepts, Berkeley, CA). A p value of less
than 0.05 was considered significant.
Multivariate regression analysis
Other variables among the 32 cases were investigated as
risk factors for occurrence of HCC. Independent factors of
sex, age, CH or LC, ALT level, AST level, platelet count,
HCV RNA concentration (more than 100 kiu/ml vs less than
100 kiu/ml), HCV genotype (genotype 1 vs genotype 2), and
changes in zinc concentration were identified by logistic
regression analysis using a stepwise method of analysis of
factors for the risk of developing HCC using SPSS 11.0
software (SPSS Inc., Chicago, IL). Furthermore, we investi-
gated the factors at the start of the study that contributed to
whether patients administered polaprezinc become zinc
responders. Independent factors of sex, age, CH or LC, ALT
level, AST level, platelet count, HCV RNA concentration
(more than 100 kiu/ml vs less than 100 kiu/ml), HCV geno-
type (genotype 1 vs genotype 2), and serum zinc concentra-
tion were identified by the Cox proportional hazard model
using a stepwise method of analysis of factors for the risk of
developing HCC using SPSS11.0 software (SPSS Inc.).
Results
Evaluation of zinc concentrations in C-viral chronic liver
disease
In patients with C-viral chronic liver diseases, the median
zinc concentration was 65.0 μg/dl (range; 50–109) in the CH
group and 53.0 μg/dl (29–91) in the LC group. The median
zinc concentration in the LC group was significantly lower
than that in the CH group (p = 0.0006). The median zinc
concentration of the polaprezinc administration group was
64.0 μg/ml (range; 41–88) and of the untreated group was
53.5 μg/dl (range; 35–68).
Efficacy of administration of polaprezinc
We examined changes in serum zinc concentrations in
patients divided into the polaprezinc administration group
and untreated group. In the polaprezinc administration
group, compared to the initial examination, 15/32 (46.9%)
patients were zinc responders, 12/32 (37.5%) were zinc
non-responders whose serum zinc concentrations were stable
and 5/32 (15.6%) were zinc non-responders whose serum
zinc concentrations decreased. On the other hand, in the
untreated group compared to the initial examination, the
serum zinc concentrations of 1/30 (3.3%) patients had
increased at three years, in 14/30 (46.7%) they remained
stable and in 15/30 (50%) they decreased. In this analysis,
the proportion of patients whose serum zinc concentrations
increased was significantly greater in the polaprezinc
administration group than the untreated group (p<0.0001),
and the proportion of patients whose serum zinc concentra-
tions decreased in the untreated group was significantly
greater than in the polaprezinc administration group
(p<0.0001).S. Matsuoka et al.
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Next, when the polaprezinc administration group was
divided into two groups  according to the median zinc
concentration at start of the study, a high zinc group (≥64
μg/dl, n = 17) and a low zinc group (<64 μg/dl, n =1 5 ) ,  t h e
efficacy of polaprezinc administration in the low zinc group
was 11/15 (73.4%) for zinc responders, 4/15 (13.3%) for
zinc non-responders whose serum zinc concentrations were
stable and 2/15 (13.3%) for zinc non-responders whose
serum zinc concentrations decreased. On the contrary, the
efficacy of polaprezinc administration in the high zinc group
was 4/17 (23.5%) for zinc responders, 10/17 (58.8%) for
zinc non-responders whose serum zinc concentrations were
stable and 3/17 (17.7%) for zinc non-responders whose
serum zinc concentrations decreased.
Comparison of changes of zinc concentrations among
patients with or without polaprezinc administration
The changes of serum zinc concentrations in the pola-
prezinc administration group and the untreated group were
compared. The results showed that in the polaprezinc
administration group three years after the study started, the
serum zinc concentrations had increased by about 10%
compared to the level at the start of the study. However, in
the untreated group the serum zinc concentrations had
decreased by about 5% three years after the start of the study,
compared to the level at the start of the study (Fig. 1). The
polaprezinc administration group showed a significant
increase in serum zinc concentrations compared to the
untreated group (p = 0.0036). Then, the changes in the
serum zinc concentrations relative to the daily dose of zinc
administered per kg body weight were compared. In the
group of patients for whom the daily dose of zinc admin-
istered was less than 0.6 mg/kg, the serum zinc concentra-
tions increased during the early period of administration
from the level prior to administration but there was a
tendency to decrease later. However, in the group for whom
the daily dose of zinc was more than 0.6 mg/kg, the serum
zinc concentrations showed a tendency to increase from one
year after the start of administration (Fig. 2).
Next, we compared the changes in serum zinc concentra-
tions between two groups of patients who were administered
polaprezinc, those with low (low zinc group <64 μg/dl) and
high (high zinc group; ≥64 μg/dl) serum zinc concentrations
at the start of the study. The serum zinc concentrations in the
low zinc group at one year after the start of administration
had increased by 12.1 ± 19.3%, and at three years had
increased by 18.3 ± 24.8%, compared to the level at the start
of administration. On the other hand, that of the high zinc
group at one year after the start of administration had
decreased by 1.4 ± 21.3%, and at three years had decreased
by 2.3 ± 14.2%, compared to the level at the start of admin-
istration. The changes in serum zinc concentrations in the
low zinc group were significantly greater than those of the
high zinc group (Fig. 3, p = 0.0002).
Fig. 1. Changes in serum zinc concentrations in patients with
C-viral chronic hepatitis (CH) and liver cirrhosis (LC),
with and without zinc administration. The median serum
zinc concentration in the group of patients who had been
administered polaprezinc was significantly higher than
that of the untreated group (p = 0.0036).
Fig. 2. The changes in the serum zinc levels were compared
according to the quantity of polaprezinc administered
per kg body weight. In the group administered less than
0.6 mg/kg zinc, the serum zinc level increased above
that before the start of administration during the early
stage of administration, but decreased later. However, in
the group administered more than 0.6 mg/kg, the serum
zinc level increased continuously from one year after the
start of administration.Zinc Supplementation in Hepatitis C
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Comparison between the polaprezinc administration and
untreated groups in terms of changes of blood and bio-
chemical data
When the reductions of AST or ALT levels, compared to
the levels after the start of the study, were compared between
the polaprezinc administration and untreated groups, the
reductions of ALT or AST levels in the polaprezinc adminis-
tration group were significantly greater than in the untreated
group (Table 2, p = 0.0019, p = 0.0069). Furthermore, the
change of platelet counts in the polaprezinc administration
group was significantly less than in the untreated group
(p = 0.0001). However, the changes in HCV RNA levels did
not differ between the two groups (p = 0.6736). Next, when
the polaprezinc administration group was divided into high
and low zinc groups, the reductions of AST levels and ALT
levels in the low zinc group were significantly greater than
those of the high zinc group (Fig. 4; p = 0.0008, p = 0.0193).
Although a significant correlation was not found, the reduc-
tions of HCV RNA levels in the low zinc group tended to be
greater than those of the high zinc group (p = 0.0506).
However, the change of platelet counts did not differ
between the low and high zinc groups (p = 0.3169).
Although the achievement of reduction of AST or ALT
levels was significantly greater for the zinc responders than
Table 2. Comparison of the rate of changes of AST levels, ALT levels, platelet counts and HCV RNA levels between the polaprezinc
administrationsgroup and untreated group, after the day of registration
Mean (%) ± standard deviation (S.D.) are shown. AST: aspartate aminotransferase; ALT: alanine aminotransferase. *p = 0.0019 by the
Repeated measure ANOVA for the comparison between Polaprezinc and Untreated groups, ¶p = 0.0069 by the Repeated measure ANOVA
for the comparison between Polaprezinc and Untreated groups, ‡p = 0.0001 by the Repeated measure ANOVA for the comparison
between Polaprezinc and Untreated groups.
Months
AST* ALT¶ Platelet count‡ HCV RNA
Polaprezinc Untreated Polaprezinc Untreated Polaprezinc Untreated Polaprezinc Untreated
+2 Months −12.4 ± 23.6 8.9 ± 29.1 −15.7 ± 29.0 4.7 ± 30.0 0.6 ± 8.2 −7.5 ± 7.4 −19.4 ± 38.0 −9.2 ± 33.3
+4 Months 17.2 ± 29.3 9.8 ± 49.0 −20.8 ± 31.6 9.5 ± 64.6 0.2 ± 8.1 −5.8 ± 10.1 −22.9 ± 42.5 −4.1 ± 29.6
+6 Months −21.2 ± 30.9 16.5 ± 65.9 −26.5 ± 41.0 7.6 ± 116.3 0.9 ± 10.1 −5.7 ± 8.8 −17.2 ± 43.9 3.1 ± 32.6
+8 Months −23.1 ± 21.7 11.6 ± 54.6 −23.8 ± 34.7 11.6 ± 84.6 0.3 ± 6.2 −8.3 ± 7.2 −17.9 ± 41.9 −5.9 ± 50.5
+10 Months −24.7 ± 25.0 9.7 ± 49.3 −29.9 ± 31.3 5.2 ± 58.8 0.7 ± 11.2 −8.7 ± 7.3 −16.1 ± 51.9 −17.6 ± 49.9
+12 Months −15.6 ± 36.4 10.6 ± 57.8 −22.0 ± 37.8 5.6 ± 81.1 0.1 ± 7.9 −8.3 ± 10.4 −11.8 ± 49.5 −3.4 ± 65.5
+14 Months −9.1 ± 36.1 10.5 ± 55.5 −17.4 ± 36.6 7.3 ± 67.2 2.7 ± 13.5 −6.7 ± 13.0 −13.4 ± 53.4 6.0 ± 70.1
+16 Months −9.2 ± 44.3 16.9 ± 58.1 −9.7 ± 44.1 11.0 ± 69.9 3.9 ± 18.1 −7.2 ± 9.5 −21.0 ± 45.4 3.9 ± 58.4
+18 Months −16.9 ± 29.2 16.8 ± 49.5 −21.3 ± 32.5 11.4 ± 60.8 1.0 ± 11.1 −8.8 ± 12.9 23.1 ± 184.0 2.9 ± 57.2
+20 Months −8.6 ± 51.7 9.1 ± 41.3 −15.8 ± 43.4 13.6 ± 74.0 1.3 ± 10.7 −10.7 ± 11.8 2.4 ± 77.8 10.5 ± 64.7
+22 Months −15.9 ± 50.0 6.2 ± 38.8 −22.2 ± 45.6 8.4 ± 51.9 1.4 ± 11.3 9.8 ± 12.1 −17.6 ± 51.7 10.1 ± 61.8
+24 Months −12.8 ± 34.2 14.7 ± 49.9 −18.7 ± 41.0 8.3 ± 46.0 0.8 ± 13.0 −8.8 ± 10.7 6.9 ± 86.6 10.5 ± 59.8
+26 Months −15.3 ± 42.5 9.1 ± 52.0 −18.8 ± 40.8 7.9 ± 56.4 −2.5 ± 13.0 −8.1 ± 12.6 −16.2 ± 60.3 6.1 ± 70.1
+28Months −15.9 ± 39.7 13.8 ± 54.6 −25.9 ± 40.6 10.0 ± 74.5 −1.5 ± 15.0 9.4 ± 15.1 7.4 ± 100.6 12.5 ± 69.1
+30Months −18.0 ± 32.9 13.0 ± 50.4 −24.2 ± 37.7 13.0 ± 54.4 −4.5 ± 11.9 −11.6 ± 14.3 1.3 ± 78.4 5.4 ± 61.2
+32 Months −18.0 ± 33.4 17.6 ± 77.6 −26.2 ± 34.7 16.4 ± 91.0 −4.9 ± 15.4 −11.4 ± 12.8 −4.1 ± 76.2 9.8 ± 66.9
+34 Months −21.4 ± 3.19 19.9 ± 66.6 −25.5 ± 36.9 17.7 ± 73.6 −5.5 ± 16.2 −10.8 ± 14.1 −5.2 ± 66.5 4.0 ± 52.8
+36 Months −20.5 ± 37.1 22.2 ± 69.9 −26.2 ± 42.9 18.5 ± 70.0 −5.6 ± 14.7 −5.2 ± 19.9 −10.1 ± 65.4 12.2 ± 51.6
Fig. 3. Comparison of changes of serum zinc concentrations in
the polaprezinc administration group between the low
zinc group, whose serum zinc concentrations were
below 64 μg/dl, and the high zinc group, whose serum
zinc concentrations were above 64 μg/dl. The change of
serum zinc concentrations in the low zinc group was
significantly greater than that of the high zinc group
(p = 0.0002).S. Matsuoka et al.
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the zinc non-responders in the low group (p = 0.0274), there
was no such difference in the high group (p = 0.5349).
The cumulative incidence of HCC in patients with C-viral
CH or LC
The incidence of HCC development after the initial
examination in patients with C-viral liver disease was 4/48
(3.8%) for CH and 4/14 (28.6%) for LC, up to March 2005.
The cumulative incidence of HCC, the assessment of which
was started prospectively after the initial measurement of the
zinc concentration, was compared between the polaprezinc
administration group (median observation period, 4.877
years, range; 1.315–5.466) and untreated group (median
observation period, 5.167 years, range; 1.271–5.436). HCC
occurred in four patients (12.5%) in the polaprezinc admin-
istration group and in four patients (12.1%) in the untreated
group. The cumulative incidence of HCC over three years
was 13.1% in the polaprezinc administration group and
13.3% in the untreated group. The difference between the
two groups was not statistically significant. However,
considering the patients who were administered polaprezinc
according to whether they were zinc responders (15 patients;
median observation period, 4.718 years, range; 1.575–
5.419) or zinc non-responders, (17 patients; mean observa-
tion period, 5.036 years, range; 1.271–5.466), the incidence
of HCC after the initial examination was 4/17 (17.6%) for
the zinc non-responders and 0/15 for the zinc responders.
The incidence of HCC after the initial examination was 4/5
(80%) for the zinc non-responders whose serum zinc
concentrations decreased and 0/12 for the zinc non-
responders whose serum zinc concentrations were stable.
The cumulative incidence of HCC was compared between
these groups. The cumulative incidence of HCC over five
years was 26.1% in the zinc non-responders and 0% in the
zinc responders (Fig. 5).
Then we compared the changes of serum zinc concentra-
tion with or without HCC development in patients with
polaprezinc administration group and the control group. The
serum zinc concentrations in patients who developed HCC
decreased significantly compared to those who did not,
however, the changes of serum zinc concentrations in the
control group did not differ significantly between those who
developed HCC and those who did not (Fig. 6a, b).
Multivariate analysis
In order to identify risk factors for the development of HCC
in patients administered polaprezinc, univariate analyses
were made using logistic regression analysis (Table 3). The
analyses revealed that zinc non-response was a significant
risk factor (risk ratio; 0.048, 95% confidence interval (CI);
0.003–0.712, p = 0.0274), although a low platelet count also
was a significant risk factor (risk ratio; 0.684, 95% CI;
0.475–0.984,  p = 0.0408). Then, we examined the risk
factors for the development of HCC in patients administered
polaprezinc by multivariate analysis using logistic regres-
sion analysis. The analyses revealed that no significant risk
factor was observed. Furthermore, in order to identify
factors contributing to zinc non-responsiveness to pola-
prezinc administration, multivariate analyses were made
using the Cox proportional hazard model. The analyses
revealed that liver cirrhosis (risk ratio; 0.001, 95% CI;
0.000246–0.512) and high serum zinc concentration at the
start of the study (risk ratio; 0.734, 95% CI; 0.556–0.968)
were contributory factors.
Fig. 4. When the polaprezinc administration group was divided into two, the high zinc group and the low zinc group, the reductions of
AST levels and ALT levels in the low zinc group were significantly greater than those of the zinc high group (p = 0.0008,
p = 0.0193).Zinc Supplementation in Hepatitis C
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Discussion
Polaprezinc is composed of zinc and L-carnocin. In Japan,
it has been used to treat gastric ulcers in general clinical
practice since 1994. The medicine we used in this study
was Promac granules, 1.0 g/day. Promac contains 150 mg of
polaprezinc per gram and also contains D-mannitol, corn-
starch, calmerose calcium, polyvinyl pyrrolidone K, and
aminoalkylacrylate polymer E as additives. Promac was
administered orally twice a day, after breakfast and after
dinner, to a total of 1.0 g. Therefore, the daily administration
of zinc was 33.9 mg. In this study, we compared the long-
term outcome between the Promac (polaprezinc) administra-
tion group and the untreated group. The results showed that,
in the polaprezinc administration group, the average serum
zinc concentrations had increased by 9.8% three years after
the treatment started compared to the level before the start
of treatment. However, in the untreated group, the serum
Fig. 5. The cumulative incidence of HCC was compared between the responders and the non-responders, based on changes in serum
zinc concentrations between the initial and final examinations. The cumulative incidence of HCC over four years was 24.9%
in the zinc non-responders and 0% in the zinc responders. The cumulative incidence of HCC over four years in the zinc
responders was clearly less than that in the zinc non-responders.
Fig. 6. Changes of serum zinc concentration in patients with or without HCC development in the polaprezinc administration group and
control group. The changes of serum zinc concentrations were significantly lower in the patients who developed HCC than
those who did not (a). However, the changes of serum zinc concentrations in the control group did not differ significantly
between those who developed HCC and those who did not (b).S. Matsuoka et al.
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zinc concentrations had decreased by approximately 5%
compared to the level at the commencement of therapy.
There were fifteen cases (46.9%) in the polaprezinc admin-
istration group whose serum zinc concentrations increased,
significantly more than in the untreated group, in which
there was only one case (3.3%). On the contrary, the patients
whose serum zinc concentrations decreased numbered only
five (15.6%) in the polaprezinc administration group but 15
(50%) in the untreated group. Therefore, it was confirmed
that the serum zinc concentrations increased following the
administration of polaprezinc, even in patients with C-viral
CH or LC.
In this study, polaprezinc was administered at a fixed
amount, regardless of the height and/or weight of the patient.
When the changes in serum zinc concentrations were
compared according to the daily dose of zinc administered
per kg body weight, the number of patients who became zinc
responders was significantly higher in the group of patients
of lower weight (data not shown). Therefore, it suggested
that there were cases in which administration of the daily
dose of 150 mg polaprezinc was insufficient. In fact, in the
group that was administered a daily dose of zinc below
0.6 mg/kg, the serum zinc concentrations increased slightly
immediately after the start of administration, but after that a
tendency to decrease was observed. However, in the group
that was administered a daily dose of zinc above 0.6 mg/kg,
the serum zinc concentrations increased gradually after the
start of administration and exceeded the levels in the group
administered a daily dose of zinc less than 0.6 mg/kg.
Therefore, when polaprezinc is used clinically, attention
must be paid to the individual’s body weight.
Comparing the long-term outcomes, the polaprezinc
administration group showed a clear reduction in ALT and
AST levels, compared to the untreated group. Although the
platelet counts decreased compared to the level at the start of
administration, the reduction was clearly less than that of the
untreated group. The ALT and AST levels also had a
tendency to decrease in the group with increased zinc
concentrations. Therefore, this prospective study confirmed
that the serum zinc concentrations gradually reduced
without zinc supplementation in patients with C-viral CH or
LC. The serum zinc concentrations increased or remained
unchanged in 84.3% of patients with C-viral chronic liver
disease when zinc was administered, but 15.6% of patients
showed a reduction in their zinc concentrations. It is known
that serum zinc concentrations decreased in patients with
liver disease in parallel with the development of disease
stage because zinc absorption from the intestine decreases
and the zinc content of the liver reduces due to the decrease
in the number of functional hepatocytes [18–22]. However,
our study suggests that the serum zinc concentrations can
increase in the majority of patients if a sufficient quantity of
zinc is administered.
When the patients administered polaprezinc were divided
into two groups whose serum zinc concentrations were more
than 64 μg/dl (high zinc group) and less than 64 μg/dl
(low zinc group), the reduction of AST and ALT levels in the
low zinc group was significantly greater than in the high zinc
Table 3. Clinical characteristics of the patients with or without occurrence of HCC at the beginning of the
study
* Median (range). Gender, Genotype, Efficacy of supplementation were analyzed by chi-square test for
independence, other factors by student’s t test.
Paramater
Hepatocellular carcinoma
p value
occurrence absence
Number 4 28
Gender (male) 3 (75%) 18 (64.8%) 0.6659
Age 65.2 (59.7–67.7) 55.3 (26.5–70.1) 0.0890
AST (U/L) 73.0 (51–138) 53.5 (40–116) 0.2320
ALT (U/L) 88.5 (65–201) 89.5 (40–231) 0.7954
Platelet count (×10−4) 9.6 (8.3–17.2) 16.7 (7.4–25.7) 0.0213
Zinc concentration 51.0 (41–73) 64.5 (45–88) 0.1.09
HCV genotype
1b 4 (100%) 24 (85.8%) 0.7214
2a 0 2 (7.1%)
2b 0 2 (7.1%)
HCV RNA level (kiu/ml) 435.0 (140–710) 600.0 (7.4–850) 0.4665
Zinc supplementation 0.0493
Zinc responders 0 15 (53.6%)
Zinc non responders 4 (100%) 13 (46.4%)Zinc Supplementation in Hepatitis C
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group. Therefore, zinc supplementation in patients with CH
or LC with low serum zinc concentrations was more
effective than in those with high serum zinc concentrations.
Specifically, patients with low serum zinc concentrations
seemed to achieve a greater reduction in serum AST or ALT
levels following zinc supplementation, regardless whether
the zinc concentration increased or decreased. On the other
hand, patients with high serum zinc concentrations, whose
serum zinc concentrations did not increase with the daily
dose of zinc given, also did not achieve a reduction of ALT
levels and perhaps require a greater degree of zinc supple-
mentation. The significance of maintaining the serum zinc
concentrations at a high level in C-viral liver disease is that,
by achieving a continuous low level of ALT, it is possible to
slow the progression of liver fibrosis and, further, to restrain
the development of liver carcinogenesis. Also, in patients
with a decreased reserve of liver function, such as those with
decompensated cirrhosis, it is possible to prolong the
survival period by increasing their zinc concentrations,
leading to improvement in hyper-ammonia and recovery of
liver function. Our study showed no significant difference
in the cumulative incidence of HCC between the group
administered polaprezinc and the untreated group. However,
comparing the zinc responders and zinc non-responders,
regardless of polaprezinc administration, the cumulative
incidence of HCC was significantly lower in the former,
suggesting that the influence of zinc supplementation on the
long-term outcome of C-viral CH or LC is significant.
Therefore, we report that zinc supplementation for C-viral
CH or LC is clinically useful.
Multivariate analysis of the clinical background factors
was performed on the zinc non-responders in the group
administered polaprezinc. The results showed that there was
no significant relationship between the age, body weight or
BMI, platelet count, ALT level, AST level, or the HCV RNA
level. However, when the changes in the serum zinc concen-
trations were evaluated according to the daily dose of zinc
administered per kg body weight, in the polaprezinc admin-
istration group for whom the daily dose of zinc was more
than 0.6 mg/kg the number of cases whose serum zinc
concentrations increased compared to the level before the
start of therapy was significantly high, whereas in the group
with zinc administration at daily dose of zinc less than
0.6 mg/kg the number of cases whose serum zinc concentra-
tions decreased was significantly high. Therefore, it seems
necessary to consider the daily dose of zinc administered
per kg body weight on an individual basis and to increase
the daily dose of zinc administered per day for patients of
greater body weight. In addition, the data suggest that, for
the zinc non-responders in the polaprezinc administration
group, increasing the daily dose of polaprezinc could lead to
an improvement in the long-term outcome of the patient.
As for the reason why ALT and AST levels reduced
with zinc administration, the following may be suggested:
It is known that zinc has an anti-oxidant effect. It has an
inhibitory action on iron-dependent radical reactions and on
lipid peroxidation. It has been assumed that the state of zinc
deficiency in chronic liver disease first leads to an increase
in hepatic phospholipids, resulting in intensification of lipid
peroxidation, and thereby causes hepatic cell injury [23, 24].
Therefore, it is assumed that zinc administration inhibits
lipid peroxidation and subsequently alleviates hepatic cell
injury and improves the AST and ALT levels. Zinc com-
plexes with ferritin in hepatocytes. With zinc administration,
complexing of zinc and ferritin also increases in the liver.
This zinc-ferritin complex is readily used by apoenzymes
that require zinc. Therefore, it is suggested that the ferritin
level in hepatocytes may decrease with increasing zinc
concentration, and zinc consequently enhances the chelation
of iron in the liver. As a result, there should be a reduction in
oxidative stress from iron in the hepatocytes and a decrease
in aminotransferase levels [25]. In fact, it has been reported
that the action of polaprezinc inhibiting gastric mucosal
injury is due to the strong anti-oxidant action and membrane
stabilizing action [26–28]. Therefore, in a similar manner
in the liver, liver function improves and liver fibrosis is
suppressed by the anti-oxidant action and membrane stabili-
zation effect of polaprezinc. The reason the incidence of
HCC in zinc responders may be reduced more than that of
zinc non-responders may be as follows: Serum ALT or AST
levels reduced through the anti-oxidant effect of zinc. Also,
zinc deficiency is known to affect certain mediators of innate
immunity, such as the function of neutrophils, NK cells and
complement [29, 30]. Furthermore, the numbers and activity
of NK cells are dependent on serum zinc concentrations
[31]. Zinc supplementation results in significantly greater
numbers of cytotoxic and helper T and NK cells than are
seen in the control group [32, 33].
Finally, we also compared the changes of serum zinc
concentrations, levels of AST and ALT, and the cumulative
incidence of HCC development between the patients with
CH and those with LC. The serum zinc concentrations
increased and the serum levels of AST and ALT were
reduced after three years of polaprezinc administration in
both groups. Furthermore, in the CH group, the cumulative
incidence of HCC development in the zinc responders was
significantly lower than that in the zinc non-responders.
However, the cumulative incidence of HCC development
did not differ significantly between the zinc responders and
non-responders in the LC group. We assume that liver
cirrhosis constitutes a high carcinogenic state and the
development of HCC could not be prevented simply by
polaprezinc administration.
In conclusion, we performed zinc supplementation for
patients with C-viral CH and LC and the following results
were obtained: The serum zinc concentration increased inS. Matsuoka et al.
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approximately half of the patients who received the zinc
supplement. Compared to the untreated patients, the AST
and ALT levels decreased significantly. Compared to the
untreated patients, the reduction in the platelet counts was
significantly lower. The factors that inhibited increases in
serum zinc concentrations following administration of
polaprezinc included low serum zinc concentration states
such as liver cirrhosis. Furthermore, the reductions of AST
and ALT levels in the low zinc group were significantly
greater than those of the high zinc group. The zinc responders
had a significantly lower cumulative incidence of HCC than
the zinc non-responders. Thus, it was confirmed that zinc
supplementation for patients with C-viral CH or LC
improves both the degree of the liver damage and the long-
term outcome.
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